Early Improvements With Atogepant for the Preventive Treatment of Migraine
This study provides Class II evidence that atogepant 60 mg QD reduces migraine frequency and improves functional outcomes within 4 weeks of initiation in patients with EM and patients with CM.
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Yingyi Liu (ORCID: https://orcid.org/0009-0002-5243-0793)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Jonathan H. Smith (ORCID: https://orcid.org/0000-0002-2798-6805)
- Brian A. Neel (ORCID: https://orcid.org/0000-0001-8269-3717)
- Uwe Reuter (ORCID: https://orcid.org/0000-0002-8527-0725)
- Cristina Tassorelli (ORCID: https://orcid.org/0000-0003-1513-2113)
- Christopher Gottschalk (ORCID: https://orcid.org/0000-0002-1105-6910)
- Andrea M. Harriott (ORCID: https://orcid.org/0000-0003-0417-7586)
- Dagny Holle (ORCID: https://orcid.org/0000-0003-4872-0384)
- Hua Guo
- Jonathan Stokes
- Kristóf Nagy (ORCID: https://orcid.org/0009-0007-8698-941X)
Institutions
- Albert Einstein College of Medicine (US)
- University of Pavia (IT)
- Universitätsmedizin Greifswald (DE)
- AbbVie (United States) (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- West German Heart and Vascular Center Essen (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1212/wnl.0000000000210212
- Citations
- 8
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.08
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Fondazione Italiana Sclerosi Multipla
- European Commission
- Bundesministerium für Bildung und Forschung
- Ministero della Salute
- H. Lundbeck A/S
- Ipsen
- National Institutes of Health
- Allergan